Vaccine Brands

Bivalent HPV vaccine targeting HPV types 16 and 18, developed by GSK. Discontinued in most markets as part of GSK portfolio rationalization.

Prescription human papillomavirus vaccine for preventing cervical cancer and other HPV-related cancers, manufactured and marketed by Merck & Co.

Novavax's protein-based COVID-19 vaccine using recombinant nanoparticle technology and Matrix-M adjuvant, FDA emergency use authorized July 13, 2022, with a biologics license application (BLA) approved May 19, 2025, offering a protein subunit alternative to mRNA-based COVID-19 vaccines for adults and adolescents.

Prescription combination vaccine for preventing diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae type b, manufactured and marketed by Sanofi.

Merck's 23-valent pneumococcal polysaccharide vaccine (PPSV23), FDA approved in 1983 as an expansion of Merck's 14-valent formulation licensed in 1977, providing T-cell independent immune protection against 23 pneumococcal serotypes in adults aged 50 and older and high-risk individuals, now used alongside conjugate vaccines per updated CDC recommendations.

Pfizer's pneumococcal conjugate vaccine franchise, originally developed by Wyeth as Prevnar (PCV7, FDA approved February 17, 2000), succeeded by Prevnar 13 (PCV13, FDA approved February 24, 2010) and Prevnar 20 (PCV20, FDA approved June 8, 2021), one of the world's best-selling vaccines with peak annual revenues exceeding $6 billion.

Merck's live oral pentavalent rotavirus vaccine (RV5), FDA approved February 3, 2006, developed by Paul Offit and colleagues at Children's Hospital of Philadelphia, containing five human-bovine reassortant rotavirus strains (G1, G2, G3, G4, and P1A) administered as a 3-dose oral series to infants, recommended by the CDC for routine infant immunization.